With its $800 million deal for Amoun Pharmaceutical, Valeant picks up what the Egyptian drugmaker says is one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East.
Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.
Stryker has only disclosed plans for two acquisitions this year--both for private, international, hospital bed makers. The latest is an all-cash deal for Turkish hospital bed, stretcher and patient room furniture and accessory maker Muka, which is headquartered in Kayseri, Turkey.
Last month, reports said Valeant was stepping up talks on a deal for one of Egypt's largest drugmakers. And now, it's pulled the trigger.
Contract drug developer AMRI bought Spain's Gadea Pharmaceutical for $174 million, picking up a company focused on the manufacture of active ingredients and finished treatments.
Think last year was an M&A record-breaker in biopharma? 2015 is on track to top it, a new report says.
By all accounts, the bidding war for Receptos was intense. But for Celgene CEO Bob Hugin and his go-to deals chief George Golumbeski, strategically this was exactly the right time to clinch a $7.2 billion buyout deal for the biotech and its lead drug ozanimod. And after they add this latest late-stage program to the pipeline, there are still more deals to be done.
Celgene is trading $7.2 billion in cash for Receptos and its Phase III autoimmune treatment, building on some recent success in the field.
Shire's $54 billion tie-up with AbbVie--and the subsequent cancellation of that deal--shook up employees and stalled CEO Flemming Ornskov's plans to transform the company into a biotech the likes of giants Gilead, Biogen and Celgene. It also took the Dublin drugmaker off course in one of its other endeavors: dealmaking.
Mylan is dead set against a buyout bid from generics rival Teva Pharmaceutical Industries. But some U.S. consumer groups are spooked by the very talk of a deal, and they're lobbying the Federal Trade Commission against it.